More than 1 billion people live with obesity, associated with 3.7 million deaths in 2024. Yet even with rapid production expansion, GLP-1 therapies are projected to reach less than 10% of those who could benefit by 2030, according to the WHO. While Eli Lilly becomes the first pharmaceutical company to reach $1 trillion in market capitalization thanks to the success of its anti-obesity drugs, 65% of non-diabetic patients stop their GLP-1 treatment within a year, and only 38.5% continue after three years.
The WHO has just issued its first conditional recommendations for the use of GLP-1 therapies in the treatment of obesity. This medical revolution transforms lives but reveals an implacable economic equation: never before has a pharmaceutical innovation created such a profound access divide between therapeutic promise and economic reality.
Over 1 Billion Obese People Facing Access to 100 Million Treatments
According to the NCD Risk Factor Collaboration study published in 2024, more than one billion people live with obesity: 880 million adults and 159 million children and adolescents aged 5 to 19 years. The global prevalence of obesity has more than doubled between 1990 and 2022, now affecting 16% of adults over 18 years old worldwide.
Even with rapid production expansion, GLP-1 therapies are projected to reach less than 10% of those who could benefit by 2030, warns the WHO. GLP-1 penetration remains low globally, with approximately 2% of the obese population currently using these medications. Estimates project that approximately 25 million Americans will be on GLP-1 treatment by 2030, compared to 10 million in 2025.
This disproportion reveals the magnitude of the challenge. For every patient with access to GLP-1 drugs, nine others remain excluded. Without deliberate policies, access to these therapies could exacerbate existing health disparities, warns the WHO.
Eli Lilly Enters the $1 Trillion Club While 90% of Patients Remain Excluded
Eli Lilly crossed the $1 trillion market capitalization threshold on Friday, becoming the first health company in the world to join this exclusive club dominated by technology firms. Combined revenues from its anti-obesity medications Zepbound and Mounjaro are projected to total $34.3 billion in 2025.
Zepbound, the company’s GLP-1 therapy for obesity, can help people lose approximately one-fifth of their weight and shows potential for helping the heart, kidneys, and other organs. Mounjaro, the diabetes medication that shares the same active ingredient called tirzepatide, has a profound effect on the disease, helping four out of five people with uncontrolled blood sugar bring it back into a healthy range.
This meteoric rise contrasts with the reality of access. Brand-name GLP-1 drugs are priced at a level that can be out of reach for most consumers. While most major insurers and Medicare plans cover GLP-1s for type 2 diabetes, coverage of GLP-1s for obesity and weight management is much more limited and often excluded from standard plans.
In November 2025, the Trump administration announced historic agreements with Eli Lilly and Novo Nordisk reducing the monthly price of GLP-1 weight loss medications from over $1,000 to just $245 for eligible patients. Starting mid-2026, Medicare will begin covering these medications for certain patient groups.
One Patient in Twelve Remains on Treatment After Three Years
Beyond initial access, treatment continuity poses a major challenge. Among 73,895 new GLP-1 users, the cumulative incidence of treatment discontinuation was 23.6% at one year and 38.5% at three years. This statistic means that only 61.5% of patients remain on treatment after three years, or approximately one patient in twelve compared to the total obese population.
Discontinuation at one year was significantly higher for patients without type 2 diabetes (65.1%) compared to those with diabetes (45.8%). In the real world, discontinuation rates remain high: 46.5% among people with diabetes and 64.8% among those without diabetes, primarily due to high cost and adverse gastrointestinal effects.
Any benefit gained during GLP-1 medication use is quickly lost when patients stop. These results underscore the importance of maintaining continuous GLP-1 treatment to sustain cardiovascular benefits. GLP-1 discontinuation was associated with significant weight regain: on average 5.63 kg and 5.81% of body weight.
Economic Inequality Determines Access to Revolutionary Treatments
Each one percentage point increase in out-of-pocket cost per 30-day supply of GLP-1 was associated with increased odds of discontinuation (odds ratio, 1.02). Higher income was strongly and progressively associated with lower discontinuation rates among those with type 2 diabetes. Compared to those with incomes below $30,000, discontinuation risks were 0.7 for those with incomes above $80,000.
This economic stratification of access reveals the political dimension of obesity. Approximately 55% of commercial employers currently cover GLP-1s for obesity, but 15% of those have abandoned coverage due to unsustainable costs. Patients had significantly higher odds of discontinuation at 12 months if they were Black or Hispanic, male, and enrolled in Medicare or Medicaid.
The WHO calls on the global community to consider strategies to expand access, such as pooled procurement, tiered pricing, and voluntary licensing. GLP-1 patents must expire in major markets such as China, India, Brazil, Canada, and Turkey, where 40% of the world’s population (and approximately 33% of adults considered obese) live.
The WHO Recommends But With Strict Conditions
With the new guideline, the WHO issues conditional recommendations for the use of these therapies to support people living with obesity. While the efficacy of these therapies in treating obesity and improving metabolic and other outcomes is evident, the recommendation is conditional due to limited data on their long-term efficacy and safety.
Although GLP-1 therapies represent the first effective treatment option for obese adults, the WHO directive emphasizes that medications alone will not solve the problem. Intensive behavioral interventions, including structured interventions involving healthy eating and physical activity, can be offered to adults living with obesity prescribed GLP-1 therapies. This is based on low-certainty evidence suggesting this may improve treatment outcomes.
GLP-1s have been added to the List of Essential Medicines for diabetes but not for obesity, despite the WHO’s obesity treatment guidelines published in December 2025 recommending their use. This dissonance reveals tensions between scientific recognition and economic accessibility.
The fracture created by GLP-1s surpasses that of any previous pharmaceutical innovation. For the first time, a revolutionary therapy simultaneously generates record capitalizations and massive exclusion of potential beneficiaries. Between proven efficacy and rationed access, humanity discovers that medical innovation can deepen as many inequalities as it resolves.
Sources
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity
- How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 - JP Morgan
- Eli Lilly becomes first drugmaker to hit $1 trillion in market value - BioPharma Dive
- Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors - PMC
- Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity - medRxiv
- Prevalence of Obesity - World Obesity Federation
- Obesity and overweight - WHO